Quantum Double Dot as Quantum Computer Unit

In this work, we have investigated the exchange interaction of two electrons in double lateral quantum dot (which is the base of quantum gate) under effect of external magnetic field, electric field and inter dot distance between double dots. From similarity between double quantum dots and molecule, we have used molecular physics approaches (Hitler London and Hund Mullikan approximation method) to investigate our system. We also show the magnetization behavior as function of magnetic field

Investigation of the viable role of oil sludge-derived activated carbon for oily wastewater remediation

A wide range of studies has been carried out to describe the equilibrium data of adsorption for the surface adsorption process. However, no extensive investigation has been carried out to evaluate the oil sludge based activated carbon surface adsorption. Therefore, the possibility of carbon active production using different oil sludges and consequently the adsorption mechanism of these kind of adsorbents is still unknown. In this study, a novel low-cost approach was introduced to synthesize the activated carbon using oil sludge applying a two-step process including carbonization and chemical activation. In this way, four different types of oil sludges were characterized and then applied to synthesize different carbon actives and their performance were investigated as an adsorbent. The results showed that all synthesized activated carbons, with about 6% ash and pH = 7 and the specific surface area of 110 m2/gr, have the ability to treatment of oily wastewater; which can be referred to the high carbon content (>80%). The iodine number and the efficiency of prepared activated carbon were obtained as 406.8 mg/g and 94%, respectively. The adsorption process was also studied at different process conditions such as temperature (308–338 K), pH value (3–9) and adsorbent amount (50–200 mg/L) to find the optimum condition for wastewater treatment. The results show that the pH value has an optimum in the adsorption rate (the maximum adsorption was measured at pH = 5) and the adsorption capacity can be reduced by increasing the temperature or decreasing the adsorbent amount. Moreover, three different adsorption isotherm models were applied, i.e., Langmuir, Temkin, and Freundlich isotherms; which the Langmuir equation was more suitable than others investigated isotherm models with R2 ≈ 0.999

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety of casirivimab and imdevimab administered in combination in patients admitted to hospital with COVID-19. Methods: RECOVERY is a randomised, controlled, open-label platform trial comparing several possible treatments with usual care in patients admitted to hospital with COVID-19. 127 UK hospitals took part in the evaluation of casirivimab and imdevimab. Eligible participants were any patients aged at least 12 years admitted to hospital with clinically suspected or laboratory-confirmed SARS-CoV-2 infection. Participants were randomly assigned (1:1) to either usual standard of care alone or usual care plus casirivimab 4 g and imdevimab 4 g administered together in a single intravenous infusion. Investigators and data assessors were masked to analyses of the outcome data during the trial. The primary outcome was 28-day all-cause mortality assessed by intention to treat, first only in patients without detectable antibodies to SARS-CoV-2 infection at randomisation (ie, those who were seronegative) and then in the overall population. Safety was assessed in all participants who received casirivimab and imdevimab. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between Sept 18, 2020, and May 22, 2021, 9785 patients enrolled in RECOVERY were eligible for casirivimab and imdevimab, of which 4839 were randomly assigned to casirivimab and imdevimab plus usual care and 4946 to usual care alone. 3153 (32%) of 9785 patients were seronegative, 5272 (54%) were seropositive, and 1360 (14%) had unknown baseline antibody status. 812 (8%) patients were known to have received at least one dose of a SARS-CoV-2 vaccine. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0·79, 95% CI 0·69–0·91; p=0·0009). In an analysis of all randomly assigned patients (regardless of baseline antibody status), 943 (19%) of 4839 patients allocated to casirivimab and imdevimab versus 1029 (21%) of 4946 patients allocated to usual care died within 28 days (RR 0·94, 95% CI 0·86–1·02; p=0·14). The proportional effect of casirivimab and imdevimab on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity=0·002). There were no deaths attributed to the treatment, or meaningful between-group differences in the pre-specified safety outcomes of cause-specific mortality, cardiac arrhythmia, thrombosis, or major bleeding events. Serious adverse reactions reported in seven (<1%) participants were believed by the local investigator to be related to treatment with casirivimab and imdevimab. Interpretation: In patients admitted to hospital with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab reduced 28-day mortality in patients who were seronegative (and therefore had not mounted their own humoral immune response) at baseline but not in those who were seropositive at baseline. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. METHODS: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). FINDINGS: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). INTERPRETATION: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids

Pooled analysis of WHO Surgical Safety Checklist use and mortality after emergency laparotomy

Background The World Health Organization (WHO) Surgical Safety Checklist has fostered safe practice for 10 years, yet its place in emergency surgery has not been assessed on a global scale. The aim of this study was to evaluate reported checklist use in emergency settings and examine the relationship with perioperative mortality in patients who had emergency laparotomy. Methods In two multinational cohort studies, adults undergoing emergency laparotomy were compared with those having elective gastrointestinal surgery. Relationships between reported checklist use and mortality were determined using multivariable logistic regression and bootstrapped simulation. Results Of 12 296 patients included from 76 countries, 4843 underwent emergency laparotomy. After adjusting for patient and disease factors, checklist use before emergency laparotomy was more common in countries with a high Human Development Index (HDI) (2455 of 2741, 89.6 per cent) compared with that in countries with a middle (753 of 1242, 60.6 per cent; odds ratio (OR) 0.17, 95 per cent c.i. 0.14 to 0.21, P <0001) or low (363 of 860, 422 per cent; OR 008, 007 to 010, P <0.001) HDI. Checklist use was less common in elective surgery than for emergency laparotomy in high-HDI countries (risk difference -94 (95 per cent c.i. -11.9 to -6.9) per cent; P <0001), but the relationship was reversed in low-HDI countries (+121 (+7.0 to +173) per cent; P <0001). In multivariable models, checklist use was associated with a lower 30-day perioperative mortality (OR 0.60, 0.50 to 073; P <0.001). The greatest absolute benefit was seen for emergency surgery in low- and middle-HDI countries. Conclusion Checklist use in emergency laparotomy was associated with a significantly lower perioperative mortality rate. Checklist use in low-HDI countries was half that in high-HDI countries.Peer reviewe

Global variation in anastomosis and end colostomy formation following left-sided colorectal resection

Background End colostomy rates following colorectal resection vary across institutions in high-income settings, being influenced by patient, disease, surgeon and system factors. This study aimed to assess global variation in end colostomy rates after left-sided colorectal resection. Methods This study comprised an analysis of GlobalSurg-1 and -2 international, prospective, observational cohort studies (2014, 2016), including consecutive adult patients undergoing elective or emergency left-sided colorectal resection within discrete 2-week windows. Countries were grouped into high-, middle- and low-income tertiles according to the United Nations Human Development Index (HDI). Factors associated with colostomy formation versus primary anastomosis were explored using a multilevel, multivariable logistic regression model. Results In total, 1635 patients from 242 hospitals in 57 countries undergoing left-sided colorectal resection were included: 113 (6·9 per cent) from low-HDI, 254 (15·5 per cent) from middle-HDI and 1268 (77·6 per cent) from high-HDI countries. There was a higher proportion of patients with perforated disease (57·5, 40·9 and 35·4 per cent; P < 0·001) and subsequent use of end colostomy (52·2, 24·8 and 18·9 per cent; P < 0·001) in low- compared with middle- and high-HDI settings. The association with colostomy use in low-HDI settings persisted (odds ratio (OR) 3·20, 95 per cent c.i. 1·35 to 7·57; P = 0·008) after risk adjustment for malignant disease (OR 2·34, 1·65 to 3·32; P < 0·001), emergency surgery (OR 4·08, 2·73 to 6·10; P < 0·001), time to operation at least 48 h (OR 1·99, 1·28 to 3·09; P = 0·002) and disease perforation (OR 4·00, 2·81 to 5·69; P < 0·001). Conclusion Global differences existed in the proportion of patients receiving end stomas after left-sided colorectal resection based on income, which went beyond case mix alone

Antimicrobial Activity of Marine Actinomycetes and the Optimization of Culture Conditions for the Production of Antimicrobial Agent(s)

The aim of the present study was to isolate antagonistic actinomycetes from marine sediment collected from the Red Sea coast at Hurghada city and the Suez Gulf. A total of 16 actinomycete isolates were obtained in October 2018 and their antagonistic activities were evaluated against Aeromonas hydrophila, Vibrio damsela, Staphylococcus aureus ATCC6538, Bacillus subtilis ATCC 6633, Pseudomonas aeruginosa ATCC 9027, Salmonella typhimurium ATCC 14028, Escherichia coli ATCC 19404 and Candida albicans ATCC 10231 by using the agar well diffusion method. Among the 16 isolates, 14 (87.5%) isolates exhibited antimicrobial activity against most of the tested pathogens. The most potent isolate was identified by 16S rRNA sequence analysis as Streptomyces sp. and designated Streptomyces sp. MK388207. The experimental design of Plackett-Burman was implemented to optimize the culture conditions for antimicrobial agent(s) production by the most powerful isolate against C. albicans ATCC 10231 when grown in starch nitrate broth and the data revealed that negative (–) levels of KNO3, K2HPO4 and pH and positive (+) levels of starch, MgSO4.7H2O, FeSO4 and incubation period supported the production of the antimicrobial agent(s). Growth under the optimized culture conditions led to a 1.4-fold rise in antimicrobial activity. The ethyl acetate extract of Streptomyces sp.MK388207 was subjected to gas-liquid chromatography mass spectrometry (GC MS) and revealed the presence of six fractions with the major component being phenol, 2,4-bis (1,1 dimethylethyl). The findings of this study suggested that the antagonistic marine Streptomyces, in particular Streptomyces sp MK388207, the antibacterial compounds produced by this isolate, could be used as antibiotics that could have future applications in the pharmaceutical industry

Tailoring porous organic polymers with enhanced capacity, thermal stability and surface area for perfluorooctane sulfonic acid (PFOS) elimination from water environment

Perfluorooctane sulfonic acid (PFOS), a perfluoroalkyl substance, has engendered alarm over its presence in water sources due to its intrinsic toxicity. Hence, there is a pressing need to identify efficacious adsorbents capable of removing PFAS derivatives from water. To achieve this, batch adsorption studies under various circumstances were employed to tune amorphous polymer networks regarding their morphological configuration, heat durability, surface area and capacity to adsorb PFOS in water. A facile, one-pot nucleophilic substitution reaction was employed to synthesize amorphous polymer networks using triazine derivatives as building units for monomers. Notably, POP-3 exhibited a superlative adsorption capacity, with a removal efficiency of 97.8%, compared to 90.3% for POP-7. POP-7 exhibited a higher specific surface area (SBET) of 232 m2 g−1 compared to POP-3 with a surface area of 5.2 m2 g−1. Additionally, the study emphasizes the importance of electrostatic forces in PFOS adsorption, with pH being a significant element, as seen by changes in the PFOS sorption process by both polymeric networks under neutral, basic and acidic environments. The optimal pH value for the PFOS removal process using both polymers was found to be 4. Also, POP-7 exhibited a better thermal stability performance (300 °C) compared to POP-3 (190 °C). Finally, these findings indicate the ease with which amorphous polymeric frameworks may be synthesized as robust and effective adsorbents for the elimination of PFOS from waterbodies.Validerad;2023;Nivå 2;2023-10-18 (joosat);CC BY 4.0 LicenseFunder: Deanship of Scientifc Research, King Khalid University, (Grant Number RGP.2/133/44)</p

Investigation of the viable role of oil sludge-derived activated carbon for oily wastewater remediation

A wide range of studies has been carried out to describe the equilibrium data of adsorption for the surface adsorption process. However, no extensive investigation has been carried out to evaluate the oil sludge based activated carbon surface adsorption. Therefore, the possibility of carbon active production using different oil sludges and consequently the adsorption mechanism of these kind of adsorbents is still unknown. In this study, a novel low-cost approach was introduced to synthesize the activated carbon using oil sludge applying a two-step process including carbonization and chemical activation. In this way, four different types of oil sludges were characterized and then applied to synthesize different carbon actives and their performance were investigated as an adsorbent. The results showed that all synthesized activated carbons, with about 6% ash and pH = 7 and the specific surface area of 110 m2/gr, have the ability to treatment of oily wastewater; which can be referred to the high carbon content (&gt;80%). The iodine number and the efficiency of prepared activated carbon were obtained as 406.8 mg/g and 94%, respectively. The adsorption process was also studied at different process conditions such as temperature (308–338 K), pH value (3–9) and adsorbent amount (50–200 mg/L) to find the optimum condition for wastewater treatment. The results show that the pH value has an optimum in the adsorption rate (the maximum adsorption was measured at pH = 5) and the adsorption capacity can be reduced by increasing the temperature or decreasing the adsorbent amount. Moreover, three different adsorption isotherm models were applied, i.e., Langmuir, Temkin, and Freundlich isotherms; which the Langmuir equation was more suitable than others investigated isotherm models with R2 ≈ 0.999.Validerad;2023;Nivå 2;2023-02-24 (joosat);Funder:  King Khalid University (RGP.2/182/43)Licens fulltext: CC BY License</p

Synthesizing and Characterizing a Mesoporous Silica Adsorbent for Post-Combustion CO₂ Capture in a Fixed-Bed System

MCM-41, a mesoporous silica with a high surface area and hexagonal structure, was synthesized, and commercial nano-silicon dioxide (SiO2) was used as a solid adsorbed in post-combustion CO2 capture. The CO2 adsorption experiments were conducted in a fixed-bed adsorption system using 5–15 vol.% CO2/N2 at a flow rate of 100 mL/min at varying temperatures (20–80 °C) and atmospheric pressure. Analyses (X-ray diffraction, nitrogen adsorption-desorption isotherms, Fourier-transform infrared spectroscopy, and transmission electron microscopy (TEM)) revealed that the synthesized MCM-41 has mesoporous characteristics: a high surface area and large pore volumes. The CO2 adsorption capacity of MCM-41 and commercial nano-SiO2 increased considerably with increasing CO2 concentration and temperature, peaking at 60 °C. Below 60 °C, dynamics rather than thermodynamics governed the adsorption. Increasing the temperature from 60 to 80 °C decreased the adsorption capacity, and the reaction became thermodynamically dominant. Additionally, compared with commercial nano-SiO2, the MCM-41 sorbent demonstrated superior regenerability and thermal stability